Resultados de búsqueda - Gerald S Falchook

  • Mostrando 1 - 14 Resultados de 14
Limitar resultados
  1. 1
    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review por Kavanya Feustel, Gerald S. Falchook

    Publicado 2022-08-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  2. 2
    T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review

    T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review por Benjamin Duong, Pratyush Banskota, Gerald S. Falchook

    Publicado 2024-05-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  3. 3
    B7-H3 Inhibitors in Oncology Clinical Trials: A Review

    B7-H3 Inhibitors in Oncology Clinical Trials: A Review por Kavanya Feustel, Jared Martin, Gerald S. Falchook

    Publicado 2024-02-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  4. 4
    Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

    Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers por Martin V. Nguyen, Lydia Loof, Gerald S. Falchook

    Publicado 2020-02-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  5. 5
    Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials

    Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials por Haelee M Chin, David K Lai, Gerald S Falchook

    Publicado 2019-02-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  6. 6
    A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

    A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer por Manish R. Patel, Gerald S. Falchook, Kensuke Hamada, Lukas Makris, Johanna C. Bendell

    Publicado 2021-02-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  7. 7
    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 por Rom Leidner, Carlo Bifulco, Israel Lowy, Gerald S. Falchook, Elizabeth Stankevich, Brian Piening, Matthew G. Fury

    Publicado 2016-11-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  8. 8
    Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

    Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose por Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab

    Publicado 2021-05-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  9. 9
    PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

    PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. por Filip Janku, J Jack Lee, Apostolia M Tsimberidou, David S Hong, Aung Naing, Gerald S Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido-Laguna, Razelle Kurzrock

    Publicado 2011-01-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  10. 10
    KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

    KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. por Ignacio Garrido-Laguna, David S Hong, Filip Janku, Ly M Nguyen, Gerald S Falchook, Siqing Fu, Jenifer J Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Publicado 2012-01-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  11. 11
    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine por Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu, Razelle Kurzrock

    Publicado 2019-12-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:
  12. 12
    736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies

    736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies por Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen

    Publicado 2023-11-01
    Artículo
    Agregar a favoritos
    Guardado en:
  13. 13
    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors por Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore

    Publicado 2023-11-01
    Artículo
    Agregar a favoritos
    Guardado en:
  14. 14
    Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

    Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors por Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock

    Publicado 2014-01-01
    Enlace del recurso
    Artículo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: